Connect Biopharma Holdings CNTB
NASDAQ CNTB
$0.79 -0.08 (-9.32%)
As of: Oct 21, 2026 · 2:54 PM EDT

Connect Biopharma Holdings (CNTB) EBITDA Margin (2024 - 2026)

Updated

Connect Biopharma Holdings' EBITDA Margin was -630.17% in Q2 2026, up 26980.25 percentage points from -27610.42% a year earlier and up 10874.57 percentage points from the prior quarter.

Analysis

Connect Biopharma Holdings (CNTB) EBITDA Margin (2024 - 2026) Analysis & Trends

On a trailing twelve-month basis, Connect Biopharma Holdings' EBITDA Margin was -2361.29% through Jun 30, 2026, up 64.05 percentage points year-over-year; for FY2025, it was -89640.63%, down 89556.92 percentage points from FY2024.

  • In earlier years, EBITDA Margin was -83.71% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.82 Bn 1,105.41 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 617.41 Bn 535.94 Bn 17.26 Bn 35.95%
3 AbbVie 501.29 Bn 474.40 Bn 12.70 Bn 49.01%
4 Merck 368.15 Bn 322.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.07 Bn 261.06 Bn 11.24 Bn -
6 Astrazeneca 260.90 Bn 234.58 Bn 12.86 Bn 33.11%
7 Amgen 236.34 Bn 191.74 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.00 Bn 165.20 Bn 6.22 Bn -124.26%
9 Pfizer 169.72 Bn 116.36 Bn 10.94 Bn 39.16%
10 Connect Biopharma Holdings 49.90 Mn -126.77 Mn - -630.17%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -630.17%
Mar 31, 2026 -11,504.73%
Sep 30, 2025 -109,362.50%
Jun 30, 2025 -27,610.42%
Dec 31, 2024 -1,355.44%
Sep 30, 2024 -1,121.41%
API Access

Connect Biopharma Holdings EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CNTB&period=max&api_key=YOUR_API_KEY